MARKET

PTN

PTN

Palatin Tech
AMEX
0.9579
-0.0921
-8.77%
Closed 19:58 02/10 EST
OPEN
1.050
PREV CLOSE
1.050
HIGH
1.080
LOW
0.9000
VOLUME
1.33M
TURNOVER
0
52 WEEK HIGH
4.650
52 WEEK LOW
0.6800
MARKET CAP
18.73M
P/E (TTM)
-0.4844
1D
5D
1M
3M
1Y
5Y
1D
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
PR Newswire · 20h ago
Weekly Report: what happened at PTN last week (0203-0207)?
Weekly Report · 1d ago
Palatin Technologies Announces $4.7 Mln Direct Offering
NASDAQ · 4d ago
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Palatin Technologies prices 4.69M shares in direct offering
Seeking Alpha · 4d ago
Palatin to sell 4.69M shares at $1.00 in registered direct offering
TipRanks · 4d ago
*Palatin Announces $4.7M Registered Direct Offering and Concurrent Private Placement
Dow Jones · 4d ago
Press Release: Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Dow Jones · 4d ago
More
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.

Webull offers Palatin Technologies Inc stock information, including AMEX: PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.